Home / Deep Research / Medullary Thyroid Carcinoma

Medullary Thyroid Carcinoma

Disease Pathophysiology Research Report

2026-01-24
Falcon MONDO:0015277 Model: Edison Scientific Literature 26 citations

Disease Pathophysiology Research Report

Target Disease

  • Disease Name: Medullary Thyroid Carcinoma (MTC)
  • MONDO ID:
  • Category: Neuroendocrine carcinoma of the thyroid gland

Pathophysiology Description

Medullary thyroid carcinoma arises from parafollicular C-cells of neural crest origin and characteristically secretes calcitonin and often carcinoembryonic antigen (CEA). Approximately 25% of cases are hereditary due to germline RET mutations (MEN2 syndromes), while ~75% are sporadic with frequent somatic RET mutations; RAS family mutations (HRAS/KRAS/NRAS) are the predominant alternative drivers in RET-wild-type tumors (mutually exclusive with RET) (gild2023medullarythyroidcancer pages 1-2, lagana2023theevolvingtreatment pages 1-3). Constitutive activation of the RET receptor tyrosine kinase engages RAS/MAPK and PI3K/AKT/mTOR signaling, driving proliferation, survival, migration, and altered differentiation; RAS mutations similarly activate these pathways (gild2023medullarythyroidcancer pages 3-4, barletta2021genomicsandepigenomics pages 10-12, lagana2023theevolvingtreatment pages 1-3). Epigenetic dysregulation (DNA methylation changes, overexpression of EZH2 and SMYD3, and miRNA alterations such as miR-375) correlates with aggressive phenotypes and prognosis (sahakian2023molecularbasisand pages 13-15, barletta2021genomicsandepigenomics pages 10-12).

Clinically, MTC exhibits hormone-mediated syndromes: calcitonin (and related peptides) are implicated in diarrhea and flushing; ectopic ACTH secretion can cause Cushing syndrome in a minority of patients. Surgical resection is the only curative option for localized disease; systemic therapy is reserved for progressive/symptomatic metastatic disease, where selective RET inhibitors (selpercatinib, pralsetinib) now provide high response rates and durable control with improved tolerability compared to multikinase inhibitors (MKIs) such as vandetanib and cabozantinib (lagana2023theevolvingtreatment pages 3-5, gild2023medullarythyroidcancer pages 1-2, lagana2023theevolvingtreatment pages 1-3, sahakian2023molecularbasisand pages 15-16).

Key recent expert consensus emphasizes universal germline RET testing for all MTC patients, somatic profiling to guide targeted therapy, and recognition of acquired resistance mechanisms (on-target RET mutations and bypass signaling) that motivate next-generation inhibitors and rational combinations (gild2023medullarythyroidcancer pages 1-2, gild2023medullarythyroidcancer pages 10-10, lagana2023theevolvingtreatment pages 1-3).

Table (click to expand)
Category Entity (ontology / identifier) Role in MTC Pathophysiology Key Evidence (DOI URL, year; citation)
Driver oncogene RET (HGNC:9967) Germline and somatic activating point mutations, indels and fusions → constitutive RTK activity that drives proliferation, survival and migration via downstream RAS/MAPK and PI3K/AKT signaling DOI: https://doi.org/10.1186/s12964-024-01837-x (2024); DOI: https://doi.org/10.3390/cancers15194865 (2023) (zhang2024moleculargeneticstherapeutics pages 5-6, sahakian2023molecularbasisand pages 1-2)
Oncogenes (mutually exclusive with RET) HRAS / KRAS / NRAS (HGNC:5005, 6407, 7771) Frequent drivers in RET-wild-type sporadic MTC; activate MAPK/PI3K pathways; associated with distinct biology and generally less aggressive phenotype vs RET M918T DOI: https://doi.org/10.1007/s12022-021-09664-3 (2021); review summarizing prevalence (2023) (barletta2021genomicsandepigenomics pages 3-4, lagana2023theevolvingtreatment pages 1-3)
Cell type / origin Parafollicular C-cell (CL:0000198) — Thyroid (UBERON:0002046) Neuroendocrine origin; C-cells synthesize and secrete calcitonin and often CEA — used as sensitive tumor biomarkers and mediators of hormone-related symptoms (diarrhea, flushing) DOI: https://doi.org/10.1210/endrev/bnad013 (2023); clinical summaries (2023) (gild2023medullarythyroidcancer pages 1-2, lagana2023theevolvingtreatment pages 1-3)
Secreted biomarkers / chemical entities Calcitonin (UniProt P01258), CEA (protein) Serum calcitonin highly sensitive for disease burden; rising CEA indicates progression/dedifferentiation and paraneoplastic syndromes (diarrhea, flushing, rare ectopic ACTH) Clinical/guideline summaries (2023) (gild2023medullarythyroidcancer pages 1-2, lagana2023theevolvingtreatment pages 1-3)
Signaling pathway (GO) GO:0007169 — transmembrane receptor protein tyrosine kinase signaling Canonical RET signaling node initiating downstream cascades (PLCγ, Src, RAS/MAPK, PI3K/AKT) that mediate proliferation, survival and migration Mechanistic reviews (2023–2024) DOI: https://doi.org/10.1210/endrev/bnad013 (2023), https://doi.org/10.1186/s12964-024-01837-x (2024) (gild2023medullarythyroidcancer pages 3-4, zhang2024moleculargeneticstherapeutics pages 5-6)
Signaling pathway (GO) GO:0000187 — activation of MAPK activity MAPK/ERK cascade is a principal downstream effector of RET and RAS mutations driving proliferation and tumor growth Mechanistic reviews and genomic studies (2021–2023) (barletta2021genomicsandepigenomics pages 3-4, gild2023medullarythyroidcancer pages 3-4)
Signaling pathway (GO) GO:0043491 — protein kinase B (AKT) signaling PI3K→AKT→mTOR axis activated downstream of RET/RAS; implicated in survival, metabolism and therapeutic targeting (mTOR pathway activation in some MTC) Genomic/functional reports (2021, 2023) (barletta2021genomicsandepigenomics pages 10-12, gild2023medullarythyroidcancer pages 3-4)
Epigenetic regulators EZH2 (HGNC:3527), SMYD3 (HGNC:15564); DNA methylation (GO:0006306); miR-375 (miRNA) Overexpression of EZH2/SMYD3 and DNA methylation changes associate with aggressive behavior; miR-375 deregulation linked to prognosis and drug sensitivity Epigenomics reviews and studies DOI: https://doi.org/10.3390/cancers15194865 (2023); https://doi.org/10.1007/s12022-021-09664-3 (2021) (sahakian2023molecularbasisand pages 13-15, barletta2021genomicsandepigenomics pages 10-12)
Tumor microenvironment / immune PSMA expression, low-TMB immune features; investigational CAR-T targeting CEA/calcitonin/RET MTC shows variable immune features; targeted/theranostic approaches (PSMA PET/PRRT, CAR-T) and combined strategies under active investigation Translational/theranostic reviews (2023) DOI: https://doi.org/10.1210/endrev/bnad013 (2023) (gild2023medullarythyroidcancer pages 10-10)
Approved multikinase inhibitors Vandetanib (targets RET, VEGFR, EGFR) — clinical benefit: ZETA trial PFS ~30.5 vs 19.3 mo (placebo); notable off‑target AEs (diarrhea, rash, QT) Multi-target blockade reduces tumor progression but causes dose-limiting off-target toxicity; better responses in RET‑positive cases Summary review with trial metrics DOI: https://doi.org/10.3390/cancers15194865 (2023) (sahakian2023molecularbasisand pages 15-16)
Approved multikinase inhibitor Cabozantinib (targets RET, MET, VEGFR2, others) — EXAM: PFS ~11.2 vs 4.0 mo (placebo); high rates of dose reduction Broad kinase inhibition yields PFS benefit but frequent toxicity and limited OS benefit historically Trial summary and review DOI: https://doi.org/10.3390/cancers15194865 (2023) (sahakian2023molecularbasisand pages 15-16)
Selective RET inhibitors Selpercatinib (LOXO-292) — high ORR (≈69–82% in trials), durable responses and favorable tolerability; Pralsetinib (BLU-667) — ORR ~60–71% Potent on-target RET inhibition with higher ORR/PFS and improved QoL vs MKIs; central to modern management of RET‑mutant MTC Clinical trial reports and long-term updates DOI: https://doi.org/10.1056/NEJMoa2005651 (2020), long-term JCO update DOI: https://doi.org/10.1200/jco.23.02503 (2024); reviews (gild2023medullarythyroidcancer pages 10-10, sahakian2023molecularbasisand pages 15-16)
Resistance mechanisms On-target (gatekeeper V804L/M, solvent-front), off‑target/bypass pathway activation, RTK indels/compound RET mutations Resistance emerges via secondary RET kinase-domain mutations or activation of bypass pathways (e.g., MET/RAS/PI3K) — motivates next‑generation RET inhibitors and combination strategies Resistance-focused reviews DOI: https://doi.org/10.1186/s12964-024-01837-x (2024); translational reviews (2023) (zhang2024moleculargeneticstherapeutics pages 5-6, gild2023medullarythyroidcancer pages 10-10)

Table: Concise reference table mapping key genes, pathways, cell types, epigenetic factors, microenvironment notes, approved therapies and resistance mechanisms in medullary thyroid carcinoma with primary evidence DOI links and recent review citations (2021–2024).

1. Core Pathophysiology

Notable recent synthesis: “RET is… a receptor tyrosine kinase that activates multiple downstream pathways including… PI3K and MAPK; activating mutations… cause constitutive signaling” (Endocrine Reviews 2023) (gild2023medullarythyroidcancer pages 3-4). A 2024 review underscores RET as “the central initiating driver in hereditary and many sporadic MTCs,” with detailed mechanistic activation models and clinical-genetic correlations (Cell Communication and Signaling, Sep 2024) (zhang2024moleculargeneticstherapeutics pages 5-6).

2. Key Molecular Players

Representative data points: “Somatic RET alterations occur in around 60% of sporadic MTC, with many of the remainder driven by RAS mutations… RAS-mutated tumors are described as less aggressive than tumors with RET p.Met918Thr” (Endocrine Reviews 2023) (gild2023medullarythyroidcancer pages 3-4).

3. Biological Processes (GO annotations)

Directly supported elements include the RET-driven activation of MAPK and PI3K cascades (Endocrine Reviews 2023) and epigenetic alterations linked to aggressiveness (Endocrine Pathology 2021; Cancers 2023) (gild2023medullarythyroidcancer pages 3-4, barletta2021genomicsandepigenomics pages 10-12, sahakian2023molecularbasisand pages 13-15).

4. Cellular Components

5. Disease Progression

6. Phenotypic Manifestations

“Systemic symptoms arise from hormonal secretion (calcitonin and calcitonin gene-related peptide) causing diarrhea and flushing; occasional ectopic ACTH/Cushing’s is described” (Curr Treat Options Oncol 2023) (lagana2023theevolvingtreatment pages 3-5).

Expert Opinions and Authoritative Guidance

  • Universal germline RET testing is recommended for all MTC patients to identify MEN2 and guide prophylactic and therapeutic decisions (Endocrine Reviews 2023) (gild2023medullarythyroidcancer pages 1-2).
  • Somatic profiling (RET vs RAS) informs selection of selective RET inhibitors vs alternative strategies; selective RET inhibitors are preferred for RET-mutant disease due to higher efficacy and tolerability compared with MKIs (lagana2023theevolvingtreatment pages 1-3).
  • Surveillance and local therapies are appropriate for indolent metastatic disease; systemic therapy is noncurative and reserved for symptomatic or RECIST-progressive disease (lagana2023theevolvingtreatment pages 3-5).

Relevant Statistics and Data (recent)

Therapy Mechanisms Linked to Biology, and Resistance

Structured Annotations

Evidence Items with URLs and Publication Dates

Quoted statements - “RET is… a receptor tyrosine kinase that activates multiple downstream pathways including… PI3K and MAPK; activating mutations… cause constitutive signaling” (Endocrine Reviews 2023) (gild2023medullarythyroidcancer pages 3-4). - “Selpercatinib showed durable efficacy with mainly low-grade toxic effects” with ORR 69–73% and 1‑year PFS 82–92% in RET‑mutant MTC (NEJM 2020) (barletta2021genomicsandepigenomics pages 6-7).

Current Applications and Real-World Implementations

Expert Opinions and Analysis

Leading reviews emphasize that molecular stratification around RET and RAS status is central to prognosis and therapeutic decision-making, with selective RET inhibitors establishing a new standard for RET‑mutant MTC. However, acquired resistance is increasingly observed, necessitating vigilant monitoring and enrollment in trials of next‑generation inhibitors and combinations, especially where on‑target RET resistance mutations (e.g., V804L/M or solvent‑front changes) or bypass signaling are suspected (gild2023medullarythyroidcancer pages 1-2, gild2023medullarythyroidcancer pages 10-10, lagana2023theevolvingtreatment pages 1-3, zhang2024moleculargeneticstherapeutics pages 5-6).

Plan status update

Scope defined; recent literature and trial data collated (2020–2024, prioritized 2023–2024); evidence extracted for mechanisms, applications, and statistics; ontology mappings provided; summary artifact embedded.

References

  1. (gild2023medullarythyroidcancer pages 1-2): Matti L Gild, Roderick J Clifton-Bligh, Lori J Wirth, and Bruce G Robinson. Medullary thyroid cancer: updates and challenges. Endocrine Reviews, 44:934-946, May 2023. URL: https://doi.org/10.1210/endrev/bnad013, doi:10.1210/endrev/bnad013. This article has 90 citations and is from a domain leading peer-reviewed journal.

  2. (lagana2023theevolvingtreatment pages 1-3): Marta Laganà, Valentina Cremaschi, Andrea Alberti, Danica M. Vodopivec Kuri, Deborah Cosentini, and Alfredo Berruti. The evolving treatment landscape of medullary thyroid cancer. Current Treatment Options in Oncology, 24:1815-1832, Nov 2023. URL: https://doi.org/10.1007/s11864-023-01145-5, doi:10.1007/s11864-023-01145-5. This article has 11 citations and is from a peer-reviewed journal.

  3. (gild2023medullarythyroidcancer pages 3-4): Matti L Gild, Roderick J Clifton-Bligh, Lori J Wirth, and Bruce G Robinson. Medullary thyroid cancer: updates and challenges. Endocrine Reviews, 44:934-946, May 2023. URL: https://doi.org/10.1210/endrev/bnad013, doi:10.1210/endrev/bnad013. This article has 90 citations and is from a domain leading peer-reviewed journal.

  4. (barletta2021genomicsandepigenomics pages 10-12): Justine A. Barletta, Vânia Nosé, and Peter M. Sadow. Genomics and epigenomics of medullary thyroid carcinoma: from sporadic disease to familial manifestations. Endocrine Pathology, 32:35-43, Jan 2021. URL: https://doi.org/10.1007/s12022-021-09664-3, doi:10.1007/s12022-021-09664-3. This article has 64 citations and is from a peer-reviewed journal.

  5. (sahakian2023molecularbasisand pages 13-15): Nicolas Sahakian, Frédéric Castinetti, and Pauline Romanet. Molecular basis and natural history of medullary thyroid cancer: it is (almost) all in the ret. Cancers, 15:4865, Oct 2023. URL: https://doi.org/10.3390/cancers15194865, doi:10.3390/cancers15194865. This article has 22 citations and is from a poor quality or predatory journal.

  6. (lagana2023theevolvingtreatment pages 3-5): Marta Laganà, Valentina Cremaschi, Andrea Alberti, Danica M. Vodopivec Kuri, Deborah Cosentini, and Alfredo Berruti. The evolving treatment landscape of medullary thyroid cancer. Current Treatment Options in Oncology, 24:1815-1832, Nov 2023. URL: https://doi.org/10.1007/s11864-023-01145-5, doi:10.1007/s11864-023-01145-5. This article has 11 citations and is from a peer-reviewed journal.

  7. (sahakian2023molecularbasisand pages 15-16): Nicolas Sahakian, Frédéric Castinetti, and Pauline Romanet. Molecular basis and natural history of medullary thyroid cancer: it is (almost) all in the ret. Cancers, 15:4865, Oct 2023. URL: https://doi.org/10.3390/cancers15194865, doi:10.3390/cancers15194865. This article has 22 citations and is from a poor quality or predatory journal.

  8. (gild2023medullarythyroidcancer pages 10-10): Matti L Gild, Roderick J Clifton-Bligh, Lori J Wirth, and Bruce G Robinson. Medullary thyroid cancer: updates and challenges. Endocrine Reviews, 44:934-946, May 2023. URL: https://doi.org/10.1210/endrev/bnad013, doi:10.1210/endrev/bnad013. This article has 90 citations and is from a domain leading peer-reviewed journal.

  9. (zhang2024moleculargeneticstherapeutics pages 5-6): Ying Zhang, Wei-Hui Zheng, Shi-Hong Zhou, Jia-Lei Gu, Qing Yu, Yi-Zhou Zhu, Yu-Jie Yan, Zhi Zhu, and Jin-Biao Shang. Molecular genetics, therapeutics and ret inhibitor resistance for medullary thyroid carcinoma and future perspectives. Cell Communication and Signaling : CCS, Sep 2024. URL: https://doi.org/10.1186/s12964-024-01837-x, doi:10.1186/s12964-024-01837-x. This article has 16 citations.

  10. (sahakian2023molecularbasisand pages 1-2): Nicolas Sahakian, Frédéric Castinetti, and Pauline Romanet. Molecular basis and natural history of medullary thyroid cancer: it is (almost) all in the ret. Cancers, 15:4865, Oct 2023. URL: https://doi.org/10.3390/cancers15194865, doi:10.3390/cancers15194865. This article has 22 citations and is from a poor quality or predatory journal.

  11. (barletta2021genomicsandepigenomics pages 3-4): Justine A. Barletta, Vânia Nosé, and Peter M. Sadow. Genomics and epigenomics of medullary thyroid carcinoma: from sporadic disease to familial manifestations. Endocrine Pathology, 32:35-43, Jan 2021. URL: https://doi.org/10.1007/s12022-021-09664-3, doi:10.1007/s12022-021-09664-3. This article has 64 citations and is from a peer-reviewed journal.

  12. (barletta2021genomicsandepigenomics pages 6-7): Justine A. Barletta, Vânia Nosé, and Peter M. Sadow. Genomics and epigenomics of medullary thyroid carcinoma: from sporadic disease to familial manifestations. Endocrine Pathology, 32:35-43, Jan 2021. URL: https://doi.org/10.1007/s12022-021-09664-3, doi:10.1007/s12022-021-09664-3. This article has 64 citations and is from a peer-reviewed journal.